Levi & Korsinsky launches investigation into Cellebrite DI over potential securities law violations tied to Q2 2026 earnings guidance
Executive summary: Levi & Korsinsky announced on August 13, 2026, that it is investigating Cellebrite DI Ltd. (CLBT) for potential securities law violations related to the company's disclosures about prior financial projections, after the stock dropped over 30% following its Q2 2026 earnings release. The investigation raises concerns about the reliability of Cellebrite’s forward-looking statements and could lead to legal exposure, shareholder lawsuits, or regulatory scrutiny if misrepresentations are found.
Who is involved: Cellebrite DI Ltd. (CLBT), Levi & Korsinsky (law firm), CLBT shareholders, and potentially the SEC or other regulators if violations are substantiated.
Likely next: Levi & Korsinsky will gather investor claims and assess whether to pursue a class action lawsuit; Cellebrite may issue a formal response or face increased scrutiny from regulators and investors.
Levi & Korsinsky has notified investors of a pending investigation into Cellebrite DI Ltd. (CLBT) regarding the accuracy of the company’s prior projections and related disclosures, following a more than 30% stock decline after its Q2 2026 results. The firm is examining whether the company made misleading statements to investors about its financial outlook. This follows a pattern of similar notices issued by Levi & Korsinsky against other companies on the same day, suggesting a broader scrutiny of recent earnings disclosures.
Timeline
- — Cellebrite DI Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Cellebrite DI (CLBT) (PR Newswire)
- — Is Cellebrite DI Ltd. (CLBT) A Good Stock To Buy Now? (Yahoo Finance)
Analysis — what this means
Likely next events
- Levi & Korsinsky to announce whether it will file a class action lawsuit by September 15, 2026
- Cellebrite to respond to investigation notice within 30 days (by mid-September 2026)
- Potential SEC inquiry if evidence of misleading disclosures emerges
- Shareholder demand for documents related to Q2 2026 guidance preparations
Sectors affected
- Digital forensics
- Law enforcement technology
- Cybersecurity solutions
Regulatory implications
- Possible SEC enforcement action under Rule 10b-5 for misleading statements
- Increased scrutiny on non-GAAP guidance disclosures in tech earnings
Historical parallels
- Levi & Korsinsky investigation into Nano-X Imaging (NNOX) in 2021 over similar guidance concerns
- Robbins Geller lawsuit against Teladoc (TDOC) in 2022 for alleged inflated projections
- Pomerantz claim against Fisker (FSR) in 2023 regarding pre-delivery disclosure issues